IN THE CLAIMS

Please amend the claims as follows:

1. (Cancelled)

2. (Currently Amended) An isolated peptide consisting of ~~comprising~~ SEQ ID NO:7.

3-24. (Cancelled)

25. (Currently Amended) A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a peptide that consists of ~~comprises an amino acid sequence~~ SEQ ID NO:7.

26. (Currently Amended) A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a peptide consisting ~~essentially~~ of amino acid sequence SEQ ID NO:47.

27. (Previously Presented) The pharmaceutical formulation of claim 25 or 26 that is administered in conjunction with a wound dressing.

28. (Previously Presented) The pharmaceutical formulation of claim 25 or 26 that is a sustained release formulation.

29. (Previously Presented) The pharmaceutical formulation of claim 25 or 26 that is administered in conjunction with a surgical implant.

30. (Withdrawn) A method of inhibiting hypoxia-inducible factor 1 alpha ubiquitination in a mammalian cell comprising contacting a mammalian cell with a peptide of formula I or II:

Xaa_1-Xaa_2-Xaa_3-Xaa_4-Xaa_5-Xaa_6-Xaa_7-Xaa_8-Xaa_9-Xaa_{10}-Xaa_{11}-
Xaa_{12}-Xaa_{13}-Xaa_{14}-Xaa_{15}-Xaa_{16}-Xaa_{17}-Xaa_{18}-Xaa_{19} (I)

Xaa_7-Xaa_8-Xaa_9-Xaa_{10}-Xaa_{11}-Xaa_{12} Xaa_{13}-Xaa_{14} (II)

wherein

Xaa_1, Xaa_3, Xaa_5, Xaa_{14}, Xaa_{15} and Xaa_{16} are each a separate acidic amino acid;

Xaa_2, Xaa_4, Xaa_7, Xaa_8, Xaa_{11} and Xaa_{19} are each a separate aliphatic amino acids;

Xaa_6, Xaa_{10} and Xaa_{18} are each a separate polar amino acid;

Xaa_9 is hydroxyproline;

Xaa_{12} and Xaa_{13} are separately an apolar amino acid such as methionine, glycine or proline; and

Xaa_{17} is an aromatic amino acid such as phenylalanine, tyrosine, tryptophan, phenylglycine, naphthylalanine,, -2-thienylalanine, 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine, 4-fluorophenylalanine, pyridylalanine, or 3-benzothienyl alanine.

31. (Withdrawn) The method of claim 30 wherein the acidic amino acid is aspartic acid or glutamic acid.

32. (Withdrawn) The method of claim 30 wherein the aliphatic amino acid is alanine, valine, leucine, isoleucine, t-butylalanine, t-butylalanine, N–methylisoleucine, norleucine, N-methylvaline, cyclohexylalanine,, -alanine, N-methylglycine, or -aminoisobutyric acid.

33. (Withdrawn) The method of claim 30 wherein the polar amino acid is asparagine, glutamine, serine, threonine, tyrosine, citrulline, N-acetyl lysine, methionine sulfoxide, or homoserine.

34. (Withdrawn) The method of claim 30 wherein the apolar amino acid is methionine, glycine or proline.

35. (Withdrawn) The method of claim 30 wherein the aromatic amino is phenylalanine, tyrosine, tryptophan, phenylglycine, naphthylalanine,, -2-thienylalanine, 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine, 4-fluorophenylalanine, pyridylalanine, or 3-benzothienyl alanine.

36. (Withdrawn) The method of claim 30 wherein the peptide comprises an amino acid sequence with at least 90% identity to SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:7.

37. (Withdrawn) The method of claim 30 wherein the peptide has an amino acid sequence comprising SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:7.

38. (Withdrawn) The method of claim 30 wherein the mammalian cell is a human cell and the method is performed in vivo.

39. (Withdrawn) The method of claim 30 wherein the method is performed in vitro.

40. (Withdrawn) A method of activating VEGF transcription in a mammalian cell comprising contacting a mammalian cell with a peptide of formula I or II:

Xaa_1-Xaa_2-Xaa_3-Xaa_4-Xaa_5-Xaa_6-Xaa_7-Xaa_8-Xaa_9-Xaa_{10}-Xaa_{11}-
Xaa_{12}-Xaa_{13}-Xaa_{14}-Xaa_{15}-Xaa_{16}-Xaa_{17}-Xaa_{18}-Xaa_{19} (I)

Xaa_7-Xaa_8-Xaa_9-Xaa_{10}-Xaa_{11}-Xaa_{12} Xaa_{13}-Xaa_{14} (II)

wherein

Xaa_1, Xaa_3, Xaa_5, Xaa_{14}, Xaa_{15} and Xaa_{16} are each a separate acidic amino acid;

Xaa_2, Xaa_4, Xaa_7, Xaa_8, Xaa_{11} and Xaa_{19} are each a separate aliphatic amino acids;

Xaa_6, Xaa_{10} and Xaa_{18} are each a separate polar amino acid;

Xaa_9 is hydroxyproline;

Xaa_{12} and Xaa_{13} are separately an apolar amino acid such as methionine, glycine or proline; and

Xaa_{17} is an aromatic amino acid such as phenylalanine, tyrosine, tryptophan, phenylglycine, naphthylalanine,, -2-thienylalanine, 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine, 4-fluorophenylalanine, pyridylalanine, or 3-benzothienyl alanine.

41. (Withdrawn) The method of claim 40 wherein the acidic amino acid is aspartic acid or glutamic acid.

42. (Withdrawn) The method of claim 40 wherein the aliphatic amino acid is alanine, valine, leucine, isoleucine, t-butylalanine, t-butylalanine, N–methylisoleucine, norleucine, N-methylvaline, cyclohexylalanine,, -alanine, N-methylglycine, or -aminoisobutyric acid.

43. (Withdrawn) The method of claim 40 wherein the polar amino acid is asparagine, glutamine, serine, threonine, tyrosine, citrulline, N-acetyl lysine, methionine sulfoxide, or homoserine.

44. (Withdrawn) The method of claim 40 wherein the apolar amino acid is methionine, glycine or proline.

45. (Withdrawn) The method of claim 40 wherein the aromatic amino is phenylalanine, tyrosine, tryptophan, phenylglycine, naphthylalanine,. -2-thienylalanine, 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine, 4-fluorophenylalanine, pyridylalanine, or 3-benzothienyl alanine.

46. (Withdrawn) The method of claim 40 wherein the peptide comprises an amino acid sequence with at least 90% identity to SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:7.

47. (Withdrawn) The method of claim 40 wherein the peptide has an amino acid sequence comprising SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:7.

48. (Withdrawn) The method of claim 40 wherein the mammalian cell is a human cell and the method is performed in vivo.

49. (Withdrawn) The method of claim 40 wherein the method is performed in vitro.

50-52. (Cancelled)